Single B-cell technologies have emerged as powerful screening tools to accelerate antibody discovery, offering R&D teams the potential to interrogate millions of individual antibody-secreting cells to ...

High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb’s Partners for Use in Their Own Laboratories EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (OABI) today ...

OmniAb has introduced xPloration ®, a high-throughput single B-cell screening platform that integrates AI-assisted image analysis and machine learning for deep mining of immunized antibody repertoires ...

Advancement of therapeutic antibody discovery faces time and economic constraints. Merck R&D experts address this issue using Sphere Bio's microfluidic picodroplet technology. Fast, high-throughput ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced its participation in the 21 st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the ...

This article and associated images are based on a poster originally authored by Mette Juul Jacobsen, Anastasios Glaros, Abrahan Hernandez-Hernandez, Anja Mezger, Tina Friis, and Peter Mouritzen and ...

The MarketWatch News Department was not involved in the creation of this content. -- Study demonstrated the use of immortalized B-cell libraries as a rapid and adaptable approach to therapeutic ...

xPloration Maximizes Impact for OmniAb’s Partners through Efficient and Precise Mining of Immunized Antibody Repertoires “Thorough mining of primary B-cells from immunized animals presents a major ...